Metrics as of 10/16/2026, 10:33 AM (Berlin time), refresh in progress.
Embecta Stock
Embecta Corp.
Company data
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Country
- United States
- CEO
- Devdatt Kurdikar
- Employees
- 1,850
- Market cap
- $365 M
- IPO
- 22/03/2022
Embecta Corp. is a medical technology enterprise devoted to enhancing the quality of life and health outcomes for individuals living with diabetes. Its comprehensive product portfolio includes essential tools such as pen needles, syringes, and advanced safety devices. Additionally, the company provides innovative…
Embecta stock: price history
1D
+4.4%
1W
+12.2%
1M
+26.7%
6M
-32.2%
YTD
-45.7%
1Y
-53.5%
2Y
-52.4%
5Y
–
10Y
–
Next earnings date
Next earnings date
24/11/2026 (in 38 days)
Volatility around earnings
~227% stronger price swings than usual
Ask the agents about Embecta
Analyst assessment of Embecta
PRICE TARGET LOW
US$5.00
CONSENSUS
US$5.00
MEDIAN
US$5.00
PRICE TARGET HIGH
US$5.00
0
STRONG BUY
0
BUY
2
HOLD
2
SELL
0
STRONG SELL
4
TOTAL · Hold
As of: 18/05/2026
Embecta stock metrics
P/E
4.33
P/B
-0.62
EV/EBITDA
6.21
RETURN ON EQUITY
-3.4%
NET MARGIN
7.8%
DEBT/EQUITY
-2.45
DIVIDEND YIELD
5.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
96.7%
FLOAT SHARES
54,771,701
AVG. DAILY VOLUME (30D)
1,055,620
Insider transactions (SEC)
Morris Milton Mayo
HOMBACH ROBERT J.
Mann Jeffrey Z
Elguicze Jacob
Kurdikar Devdatt
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: +4.4%
Forums (Reddit)
Institutional holders
Dividends
Comparable stocks
Frequently asked questions about Embecta stock
What does Embecta do?
Embecta Corp. is a company in the Healthcare sector, Medical - Instruments & Supplies industry, headquartered in United States.
The CEO is Devdatt Kurdikar, the company employs around 1,850 people.
The IPO was on 22/03/2022; the stock trades on NASDAQ under the ticker EMBC.
What do analysts say about Embecta stock?
4 analysts rate the stock, the consensus is Hold (as of 18/05/2026).
The average price target is US$5.00, ranging from US$5.00 to US$5.00, with a median of US$5.00.
This is an external assessment, not a statement by Market Jury.
When does Embecta report next?
The next earnings date is 24/11/2026.
Around past earnings, price swings were roughly 227% stronger than usual.
Does Embecta pay a dividend?
Yes. The last dividend was US$0.01 per share, ex-date 27/08/2026, paid on 15/09/2026.
The dividend yield is 5.0% (as of 30/06/2026).
Which stocks are comparable to Embecta?
Comparable stocks include Intuitive Surgical, Becton, Dickinson and Company, ResMed, West Pharmaceutical Services, Solventum, Baxter International, Cooper Companies and Avantor.
How can I get Embecta stock analyzed?
Clicking "Analyze stock" lets five strategies assess Embecta against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.